Netoglitazone

Potent Smoothened receptor agonist: activates the Hedgehog signaling pathway.

SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3 , with an IC 50 of 12 nM for human GSK-3β . SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s

SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3 , with an IC 50 of 12 nM for human GSK-3β . SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s

SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3 , with an IC 50 of 12 nM for human GSK-3β . SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s

SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3 , with an IC 50 of 12 nM for human GSK-3β . SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s

SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3 , with an IC 50 of 12 nM for human GSK-3β . SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s

SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of GSK3 , with an IC 50 of 12 nM for human GSK-3β . SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s

General description SB202190 aids in enhancing the self-renewal ability of neural stem cells fromNPC1-deficient mice. Application SB 202190 has been used: to investigate the role of p38mitogen-activated protein kinase (MAPK) signaling in

General description SB202190 aids in enhancing the self-renewal ability of neural stem cells fromNPC1-deficient mice. Application SB 202190 has been used: to investigate the role of p38mitogen-activated protein kinase (MAPK) signaling in

A structural analog of SB 202190 and SB 203580 that is used as a negative control in studies of p38 inhibition.

Potent, selective p38 MAPK inhibitor: orally active.

A selective p38 MAP kinase inhibitor (IC₅₀ = 44 nM for p38&alpha) that has been shown to reduce inflammatory cytokine production and is neuroprotective following oral administration in vivo.